OBJECTIVE Autosomal dominant drusen is of particular interest because of its phenotypic similarity to age related macular degeneration. Currently, mutation R345W ofEFEMP1 and, in a single pedigree, linkage to chromosome 6q14 have been causally related to the disease. We proposed to investigate and quantify the roles ofEFEMP1 and the 6q14 locus in dominant drusen patients from the UK and USA.
DESIGN Molecular genetic analysis.
PARTICIPANTS Ten unrelated families and 17 young drusen patients.
MAIN OUTCOME MEASURES Exons 1 and 2 of EFEMP1 were characterised by 5′ rapid amplification of cDNA ends and direct sequencing. Exons 1-12 ofEFEMP1 were then investigated for mutation by direct sequencing. A HpaII restriction digest test was constructed to detect the EFEMP1R345W mutation. Marker loci spanning the two dominant drusen linked loci were used to generate haplotype data.
RESULTS Only seven of the 10 families (70%) and one of the 17 sporadic patients (6%) had the R345W mutation. The HpaII restriction digest test was found to be a reliable and quick method for detecting this. No other exonic or splice site mutation was identified. Of the three families without EFEMP1 mutation, two were linked to the 2p16 region.
CONCLUSIONS EFEMP1R345W accounts for only a proportion of the dominant drusen phenotype. Importantly, other families linked to chromosome 2p16 raise the possibility of EFEMP1 promoter sequence mutation or a second dominant drusen gene at this locus. Preliminary haplotype data suggest that the disease gene at the 6q14 locus is responsible for only a minority of dominant drusen cases.
Statistics from Altmetric.com
Drusen deposits in the macular region of the retina are found in an important set of inherited blinding conditions. These may be subdivided into those conditions where drusen are the earliest and principle finding occurring before 50 years of age and those conditions where drusen are a minor secondary feature, for example, Sorsby's fundus dystrophy. All pedigrees documented to date within the former subgrouping have been reported to exhibit autosomal dominant inheritance and so are said to express a “dominant drusen” phenotype. It is not yet known whether the dominant drusen retinopathy in these different pedigrees represents one or a number of distinct disease entities.1 Eponymous types of dominant drusen include Doyne's honeycomb retinal degeneration (DHRD) and malattia leventinese (ML). In DHRD, large drusen deposits have been described at the macula and around the edge of the optic nerve head.2 3 In ML, as well as macular drusen, small, discrete drusen are also seen radiating into the peripheral retina. These radial deposits are described as continuous with or internal to the basement membrane of the retinal pigment epithelium.4Macular drusen are also a hallmark of age related macular degeneration (ARMD), a complex genetic disorder that accounts for 50% of blind registration in the developed world.5 Characteristically, drusen are seen clinically before the sixth decade of life in dominant drusen pedigrees, but later than this in ARMD.
Both ML and DHRD have been mapped to chromosome 2p166 7and a single mutation (R345W) has been identified in theEFEMP1 gene.8 This was found in pedigrees with both ML and DHRD and it has been suggested that this mutation originates from a common ancestor and that perhaps most cases of dominant drusen derive from this. More recently, a single dominant drusen pedigree has been mapped to chromosome 6q14.9 10In this study, we proposed to determine whether these molecular genetic localisations are relevant to a large cohort of dominant drusen pedigrees identified in the UK and USA.
FAMILY AND CLINICAL DATA
Ten unrelated families expressing a dominant drusen phenotype and 17 young cases without a family history (16 British and one American patient) were enrolled into the study. Informed consent for clinical and genetic assessment was obtained in accordance with the Declaration of Helsinki. The cohort comprised seven families from the UK (UK1 to UK7) and three families from the USA (US1 to US3) (table 1). Families UK1 and US2 have previously been clinically described.11 12 UK1 is descended from the patients originally described by R W Doyne.2 All subjects classified as affected exhibited soft drusen at the macula before 45 years of age. Unaffected status was assigned to those patients with a normal ophthalmic examination and over 55 years of age. Since no other type of inheritance has been described, simplex cases under 45 years of age, with retinal drusen for no other apparent cause, were classified as examples of dominant drusen.
CHARACTERISATION OF 5′ END OFEFEMP1 AND MUTATION SCREEN
The structure of the 5′ end of the EFEMP1gene including 5′ untranslated exons 1 and 2 has not been fully established. In order to be able to screen the entireEFEMP1 gene for mutations, we therefore characterised the 5′ end of the gene. Two PAC clones containing theEFEMP1 gene were isolated from the RPCI1 PAC library (de Jong), obtained from the HGMP Resource Centre, Hinxton, Cambridge. A 5 kb EcoRI subclone containing exon 3 of the gene was identified. A combination of 5′ rapid amplification of cDNA ends (RACE) and genomic sequencing was used to characterise the region upstream of exon 3 including exon 1 (GenBank accession number AY027910) and exon 2 (GenBank accession number AY027911). Using this new information, intronic primers were designed to amplify exons 1 and 2 for mutation screening. These were 1F: AACGCTGGGCTCAGCGCTC and 1R: CATCCCAACAGATGTCACC with an annealing temperature of 60°C and 2F: ACTGGAAGATTGCTCTCC and 2R: TCCATTTCAAAGGGGACGG at 55°C.
Genomic DNA was extracted from peripheral blood lymphocytes from family members using the Nucleon II kit (Nucleon Biosciences). Exons 1 to 12 were then amplified by PCR using primers as listed above for exons 1-2 and using previously described primers for exons 3-12 under standard conditions.8 Both strands of each amplified fragment were examined for mutation by direct sequencing using standard protocols.13
Since the R345W mutation removes a HpaII restriction site in exon 10, we investigated whether this could be used as an initial diagnostic test for this mutation. PCR was used to amplify a 240 bp fragment spanning exon 10 from patient DNA. The PCR products were then digested with the restriction enzymeHpaII and run out on agarose gels.
Five microsatellite marker loci, D2S2739, D2S2352, D2S2251, D2S2153, and D2S378, spanning approximately 4 cM (Marshmed map)14 of the chromosome 2p16 region linked to dominant drusen, were used to generate haplotype data. Six further marker loci were also used in the chromosome 2p16 analysis, 133018CA, 322A4AAAT, and four intragenic polymorphisms derived from introns 4, 8, 9, and 11 of the EFEMP1 gene.8 Six microsatellite marker loci, D6S460, D6S1652, D6S2258, D6S1644, D6S462, and D6S1056, mapping to the 6q14 dominant drusen linked region, were also used in selected pedigrees.
Marker loci were amplified by PCR incorporating [33P]-α-dATP and visualised by autoradiography following electrophoresis on 6% denaturing polyacrylamide gels.
Mutation screening established that seven of the 10 families (70%, four British, three American) and one of the 17 simplex cases (6%, one British patient) had the EFEMP1R345W mutation. This was further established using theHpaII restriction enzyme digestion assay (fig 1). Haplotype data generated at marker loci spanning the 4 cM linked interval of chromosome 2p16 showed that these patients all shared a common genetic haplotype across the 1 cM region D2S2251 to D2S378, including intragenic EFEMP1polymorphisms (table 1). This suggests a founder mutation. It was of particular note that the intragenic marker loci were often uninformative, for example, marker locus intron 11 was uninformative in all families studied.
Three of the 10 families and 16 of the simplex cases were found to be negative for the R345W mutation by HpaIIrestriction enzyme analysis and direct sequencing of exon 10 (fig 1). Subsequent sequencing of exons 1-9, 11, and 12 in these cases did not identify any other mutation in any exons or at splice site junctions of the EFEMP1 gene. It was noteworthy that each of the three families without the R345W mutation also had different haplotypes at the 2p16 linked locus, both from each other and from the R345W founder population. This suggests that these families are unrelated to the original common ancestor who had theEFEMP1 mutation (table 1). Interestingly, two of these families, UK5 and UK6, have previously been linked to the 2p16 disease associated locus.15 The other family, UK7, was too small for statistically significant linkage analysis. However, recombination events observed in family UK7 show convincing exclusion of the 2p16 locus (fig 2). Haplotype data for the chromosome 6q14 dominant drusen locus generated in family UK7 is presented in fig 2. Recombination events in families UK5 and UK6 excluded linkage to this locus (data not shown).
Clinical photographs of the retina of dominant drusen patients who do not have EFEMP1 R345W mutation are presented in fig 3. Typically, soft macular drusen were noted in each case. It was noteworthy that clinically, in each case, these deposits were confined to the macular region and were neither juxtapapillary (abutting the optic nerve head) nor extended in to the periphery as has been described in many dominant drusen pedigrees with the R345W mutation.3 4 11
It is clear from the work presented here thatEFEMP1 mutation including R345W accounts for a large but not an overwhelming proportion of cases of dominant drusen. Only 70% of families and more strikingly only 6% of sporadic cases showed EFEMP1 mutation. Therefore, although an EFEMP1 mutation screen should be the initial test in the molecular diagnosis of a case of retinal drusen in a patient under 50 years of age, a negative result does not exclude this clinical diagnosis. Abolition of theHpaII restriction site in exon 10, as described here for the first time, can be used to enhance the efficiency of EFEMP1 screening for the common R345W mutation (fig 1). In addition, information on untranslated exons 1 and 2 now allows for a more complete assessment of the role of this gene in subjects expressing a drusen phenotype.
It is of particular interest that two pedigrees UK5 and UK6, although showing linkage to chromosome 2p16, did not have anEFEMP1 mutation. This may be interpreted as evidence to suggest a second dominant drusen gene at this locus. Alternatively, these pedigrees may express mutations of theEFEMP1 promoter sequence. No such promoter sequence mutation has yet been associated with outer retinal dystrophy, although RB1 promoter sequence mutation has been associated with retinoblastoma.16
Another striking feature of this study was the phenotype seen in dominant drusen cases that did not haveEFEMP1 mutation. All had soft macular drusen, but none seemed to exhibit juxtapapillary or hard radial drusen (fig 3B, C). This latter feature is a cardinal sign in ML.4 In DHRD, juxtapapillary drusen are seen unless there is juxtapapillary atrophy and radial drusen are seen in some cases but not others.11 It is of interest that these ML and DHRD pedigrees have all had R345W EFEMP1mutation.8 It is possible that the juxtapapillary drusen and radial drusen are features specific to R345WEFEMP1 although the pedigree recently mapped to 6q also had members with radial drusen.10 This needs to be investigated in further studies.
Family UK7 also did not exhibit EFEMP1mutation and, significantly, haplotype analysis excluded the chromosome 2p16 locus. Chromosome 6q haplotype data, however, may suggest that the dominant drusen phenotype in UK7 is the result of mutation at this locus. The evidence for this is, however, not conclusive and other loci may be relevant. Drusen are a minor feature of a number of other mapped retinal dystrophies including Sorsby's fundus dystrophy (chromosome 22q31),17 North Carolina macular dystrophy (chromosome 6q16),18 and autosomal dominant age related macular degeneration (1q).19 Each of these loci should be included in any secondary genome search for the disease gene leading to a retinal drusen phenotype.
We gratefully acknowledge The Wellcome Trust (054517), the Foundation Fighting Blindness, and the British Retinitis Pigmentosa Society (GR524) for their financial support of this work.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.